PHARMA DEALS DURING AUGUST 2014

(Part 3 out of 3)

by Medius Associates

This table lists all the major pharma collaborations, acquisitions and mergers agreed during August 2014

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
InterMune/ Roche	Company acquisition	Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada)	8,300
MannKind/ Sanofi	Licence	Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US)	925
Charleston Laboratories/ Daiichi Sankyo*	Collaboration (co-promotion rights)	Hydrocodone combination products, inc CL-108, for acute pain and reduction of Opioid-Induced Nausea and Vomiting (OINV) (phase III)	650
Gamida Cell/ Novartis	Investment, option to acquire	Stem cell therapies including NiCord (phase I/II)	635
Beijing Jialin Pharma/ Luye Pharma	Company acquisition (58%)	CV and cancer drug portfolio	600
TARIS Biomedical/ Allergan	Company acquisition	LiRIS for interstitial cystitis / bladder pain syndrome (IC/BPS) (phase II)	587.5
Santaris/ Roche (pRED)	Company acquisition	Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics	450
Sapiens Steering Brain Stimulation/ Medtronic	Company acquisition	Deep brain stimulation technologies for neurodegenerative diseases e.g. PD and essential tremor	200
Dream Pharma/ Alvogen	Company acquisition	Generics	187
Emergent BioSolutions/ Morphosys**	Licence, joint development & commercialisation	MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical)	183
Immune Design/ Sanofi	Licence	GLAAS discovery platform to develop therapeutics for a selected food allergy	168
Guizhou Taibang Biological Products/ China Biologic	Company acquisition (19.84% stake)	Plasma-based products	87.1+
Ziopharm Oncology/ Solasia Pharma	Amendment of 2011 licence/ collaboration	Darinaparsin (Zinapar or ZIO-101) and  related organoarsenic molecules	72.2
Millennium (Takeda)/ Infinity Pharma	Option to buy out future potential royalties	IPI-145 for treatment of blood cancers (phase III)	57.5
Rush University Medical Center/  DRI Capital	Acquisition of royalty rights	Ampyra (dalfampridine) extended release tablets (marketed)	42
Alpine Biosciences/ Oncothyreon	Company acquisition	Protocells, nanoparticle technology for targeted delivery of nucleic acids, proteins, peptides, small molecules (platform)	27
Valeo Pharma/ Valeant	Product portfolio acquisition	Dermatology brands and specialty products	25.3
ViaCyte/ Janssen R&D	Rights agreement	VC-01 based on pancreatic progenitor cells to treat type 1 diabetes (preclinical)	20
Hanmi Pharm/ Luye Pharma†	Licence	Poziotinib, a pan-HER inhibitor for the treatment of cancer (phase II)	20
Abbott/ US Department of Defense	Collaboration	To develop portable blood tests to evaluate potential concussions or mild traumatic brain injuries (TBIs)	19.5

All deals are worldwide unless otherwise noted.

*    US

**  ww excluding US and Canada

†    China

Fuente: PMLiVE

Haciendo click en cada uno de los links siguientes, 

accederán a los Contenidos de nuestros 

TALLERES DE CAPACITACIÓN IN COMPANY A MEDIDA:

(translator on page)

¿Cómo INCORPORAR y APLICAR Modelos de
PENSAMIENTO ESTRATÉGICO?

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_6246.html

¿Cómo GERENCIAR EFICAZMENTE a partir del

MANAGEMENT ESTRATÉGICO?

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_3.html

¿Cómo GERENCIAR PROCESOS DE CAMBIO
y no sufrir en el intento?

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa.html

¿Cómo IMPLEMENTAR ESTRATEGIAS EFECTIVAS?

Recetas para Escenarios Turbulentos

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-taller-de.html

Consultas al mail: msg.latam@gmail.com

ó al TE: +5411-3532-0510